Pulmonary Aspergillosis and Zygomycosis

Overview

Both: environmental molds, inhaled spores. General mechanisms = General Mycology + Mucormycosis topics. THIS = pulmonary-specific manifestations.

Pulmonary Aspergillosis Spectrum (host-determined, not 4 unrelated diseases)

ABPA (Allergic Bronchopulmonary Aspergillosis): asthma/CF patients, HYPERSENSITIVITY to airway colonization (NOT tissue invasion) — mirrors TPE mechanism (fungal not filarial trigger). Worsening asthma, wheeze, BROWNISH MUCUS PLUGS, marked IgE+eosinophilia (TPE-like signature), central bronchiectasis.

Aspergilloma (“fungus ball”): colonizes PRE-EXISTING CAVITY (classic: OLD HEALED TB CAVITY — India TB burden connection), NO tissue invasion, grows free in cavity space. HEMOPTYSIS (± massive/life-threatening) = dominant symptom (erodes cavity wall vessels, not infective process).

CPA (Chronic Pulmonary Aspergillosis): slow progressive, LOCALLY INVASIVE, underlying STRUCTURAL lung disease (COPD, prior TB, bronchiectasis) WITHOUT severe immunosuppression — contrast IPA below.

IPA (Invasive Pulmonary Aspergillosis): most severe/acute. SEVERELY IMMUNOCOMPROMISED (profound prolonged NEUTROPENIA = #1 risk, post-chemo/HSCT; also steroids, transplant). ANGIOINVASIVE (same mechanism as Mucormycosis, different organism, comparably destructive). Substantial mortality even treated.

Diagnosis: GALACTOMANNAN antigen (serum/BAL) — relatively SPECIFIC to Aspergillus (contrast broader β-D-glucan, see Candidiasis/PCP topics). Culture+histopath: SEPTATE, ACUTE-ANGLE branching hyphae (KEY contrast vs Mucorales’ broad non-septate wide-angle — treatment-determining distinction, see below). Serum IgE+precipitins support ABPA specifically.

Treatment: tailored per entity —

• IPA: Voriconazole 1st line
• ABPA: oral corticosteroids (±itraconazole steroid-sparing) — treats hypersensitivity, not fungus directly
• Aspergilloma: conservative if asymptomatic, SURGERY for significant/recurrent hemoptysis (antifungals penetrate avascular fungal ball poorly)
• CPA: prolonged oral antifungal (itraconazole/voriconazole)

Pulmonary Zygomycosis (Mucormycosis)

General biology/angioinvasion/rhino-orbital-cerebral+DKA presentation = Mucormycosis topic. PULMONARY FORM: predominantly NEUTROPENIC/HEMATOLOGIC MALIGNANCY patients (overlaps IPA risk group — same neutropenia vulnerability) rather than DKA population.

CRITICAL POINT (from Mucormycosis topic, restated): standard empirical mold-infection antifungals (voriconazole, echinocandins) = NO ACTIVITY against Mucorales. Septate-vs-non-septate hyphal distinction = TREATMENT-DETERMINING finding, not academic detail.

Comparison Table

Two Mould Infections, Different Host Vulnerability Patterns

Aspergillus and the Mucorales (covered in general disease-mechanism depth under General Mycology and, for the disseminated/rhino-orbital-cerebral form specifically, under Mucormycosis) are both environmental moulds acquired by inhaling airborne spores, and both cause a genuine spectrum of pulmonary disease determined largely by host immune and structural lung status — this topic focuses specifically on the pulmonary manifestations of each, complementing the disseminated mucormycosis picture already covered under its own topic.

Pulmonary Aspergillosis — A Genuine Spectrum

Rather than a single disease, “pulmonary aspergillosis” describes a spectrum of genuinely distinct clinical entities determined by the interaction between fungal exposure and the specific host immune/structural context:

• Allergic bronchopulmonary aspergillosis (ABPA) occurs in patients with pre-existing asthma or cystic fibrosis, representing a hypersensitivity reaction to Aspergillus colonizing the airways (not tissue invasion) — mirroring, in general hypersensitivity logic, the same mechanism covered under Tropical Pulmonary Eosinophilia, though here triggered by fungal rather than filarial antigen. Presents with worsening asthma control, wheeze, and characteristically brownish mucus plugs coughed up, alongside markedly elevated serum IgE and eosinophilia (again mirroring TPE’s laboratory signature, though from a different underlying trigger), and central bronchiectasis on imaging.
• Aspergilloma (“fungus ball”) develops when Aspergillus colonizes and grows within a pre-existing pulmonary cavity — classically an old, healed tuberculous cavity, a genuinely important, specifically testable point of connection to Tuberculosis given India’s TB burden — without actually invading the surrounding lung tissue; the fungus simply grows as a free mass within the cavity space. Haemoptysis, sometimes massive and life-threatening, is the dominant, most clinically significant symptom, arising from the fungal mass eroding adjacent blood vessels within the cavity wall rather than from any systemic infective process.
• Chronic pulmonary aspergillosis (CPA) represents a slowly progressive, locally invasive form occurring in patients with underlying structural lung disease (COPD, prior TB, bronchiectasis) but without severe immunosuppression — a genuinely important, specifically testable distinction from the more acute, immunosuppression-dependent invasive form below, since CPA occurs in a host with structural rather than immune vulnerability.
• Invasive pulmonary aspergillosis (IPA) is the most severe, acutely life-threatening form, occurring specifically in the severely immunocompromised (profound, prolonged neutropenia — classically post-chemotherapy or in haematopoietic stem cell transplant recipients — being the single most important risk factor, alongside high-dose corticosteroids and solid organ transplantation), with the fungus actively invading lung tissue and blood vessels (angioinvasion) — the same angioinvasive mechanism covered under Mucormycosis, here caused by a genuinely different organism but producing a comparably destructive, vascular-thrombosis-driven pattern of tissue necrosis, and carrying substantial mortality even with treatment.

Laboratory Diagnosis

Galactomannan antigen (a component of the Aspergillus cell wall, detectable in serum or BAL fluid) is a genuinely important, relatively specific biomarker for invasive aspergillosis, used both for diagnosis and for monitoring treatment response — a real point of contrast with the broader, less organism-specific β-D-glucan marker covered under Systemic Candidiasis and Pneumocystis Pneumonia, since galactomannan is comparatively Aspergillus-specific rather than a pan-fungal marker. Culture and histopathology (showing characteristic septate, acute-angle-branching hyphae — the specific morphological contrast with Mucorales’ broad, non-septate, wide-angle-branching hyphae covered under Mucormycosis, and a genuinely important, specifically testable distinguishing point given how differently the two organism groups are treated) confirm diagnosis where tissue/fluid sampling is feasible. Serum IgE and specific anti-Aspergillus antibody/precipitins support ABPA diagnosis specifically, distinct from the antigen-based tests used for invasive disease.

Treatment

Management is genuinely tailored to the specific clinical entity rather than uniform: voriconazole is first-line for invasive pulmonary aspergillosis; oral corticosteroids (sometimes with itraconazole as a steroid-sparing adjunct) treat ABPA’s underlying hypersensitivity process rather than targeting the fungus directly with antifungals alone; aspergilloma is managed conservatively when asymptomatic, with surgical resection reserved for significant or recurrent haemoptysis, since antifungal drugs penetrate poorly into the largely avascular fungal ball itself; CPA typically needs a prolonged oral antifungal course (itraconazole or voriconazole).

Pulmonary Zygomycosis (Mucormycosis)

The Mucorales’ general biology, angioinvasive mechanism, and the classically emphasized rhino-orbital-cerebral/DKA-associated presentation are covered in full under Mucormycosis; the pulmonary form specifically occurs predominantly in neutropenic/haematological malignancy patients (a genuinely important point of overlap with invasive pulmonary aspergillosis’s risk-group profile, since both organisms exploit the same profound-neutropenia vulnerability, and the two diseases can present similarly enough on imaging and clinical grounds that distinguishing them specifically matters for treatment choice) rather than the diabetic/DKA population more classically associated with the rhino-orbital-cerebral form. The critical, specifically testable clinical point, already established under Mucormycosis but worth restating in this direct pulmonary-aspergillosis comparison context: standard antifungal agents used empirically for suspected invasive mould infection (voriconazole, echinocandins) have no activity against Mucorales at all, meaning the septate-versus-non-septate, acute-versus-wide-angle hyphal morphology distinction on direct microscopy is not merely an academic taxonomic detail but a genuinely treatment-determining finding that must be made correctly and promptly.

Comparative Summary

Short Notes (1)